Today on
Adoption of income statement and balance sheet for the financial year 2021 and discharge from liability
The AGM resolved to adopt the income statements for the financial year 2021 as well as the balance sheets as of
Allocation of the company's results
The AGM resolved, in accordance with the board of directors' proposal, that no dividend shall be paid for 2021 and that the results of the company shall be carried forward.
Election of board members and auditors, and fees to the board of directors and auditors
The AGM resolved, in accordance with the nomination committee's proposal, that the number of members of the board of directors shall be eight without deputies and that the number of auditors shall be one registered accounting firm.
In accordance with the nomination committee's proposal Jan Törnell was elected as new member of the board of directors and Magnus Björsne,
In accordance with the nomination committee's proposal the audit firm
The AGM further resolved to, in accordance with the nomination committee's proposal, that fees to the chairman of the board shall be paid with
The AGM further resolved, in accordance with the nomination committee's proposal, that board members (in addition to remuneration for expenses relating to travel and accommodation) domiciled in
The AGM further resolved, in accordance with the nomination committee's proposal, that the remuneration, for services rendered by the auditor of the company, shall be paid in accordance with approved invoice.
Principles for the appointment of the nomination committee
The AGM resolved, in accordance with the nomination committee's proposal, to adopt the principles for appointment of a nomination committee as presented in the notice convening the AGM.
Approval of the board of directors' remuneration report
The AGM resolved, in accordance with the proposal from the board of directors, to approve the remuneration report for the financial year 2021.
Adoption of guidelines for remuneration to executive management
The AGM resolved, in accordance with the proposal from the board of directors, to adopt guidelines for remuneration to senior executives, valid for the period until the end of the AGM 2026. The new guidelines are in all material aspects identical to the guidelines approved by the AGM 2020, but with the adjustment of the framework for the CEO's and other members of the executive management retirement benefits, including health insurance, to no more than a maximum thirty (30) per cent of the fixed annual cash remuneration
Amendment of the articles of association
The AGM resolved, in accordance with the board of directors' proposal, to amend the articles of association so that the board of directors may allow shareholders to vote by mail before general meetings; that the board may collect proxies in accordance with Chapter 7, Section 4 of the Swedish Companies Act; and that guidelines for remuneration to senior executives shall be adopted every four years in accordance with applicable legislation.
Authorisation for the board of directors to resolve on new issues
The AGM resolved, in accordance with the board of directors' proposal, to authorize the board of directors to, on one or several occasions and with or without deviation from the shareholders' preferential rights, resolve on new issues of shares, warrants and/or convertibles corresponding to no more than 10 per cent of the registered share capital in the company at the time of the issue resolution.
For more information, please contact
Jan Törnell, chairman of the board of directors
Jarl Ulf Jungnelius, M.D., CEO
E-mail: jungnelius@isofolmedical.com
Phone: +46 (0)709-16 89 55
The information was submitted for publication, through the agency of the contact person set out above, at
About arfolitixorin
Arfolitixorin is Isofol's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global pivotal Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
About Isofol Medical AB (publ)
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/bulletin-from-annual-general-meeting-in-isofol-medical-ab--publ--held-on-may-19--2022,c3570652
https://mb.cision.com/Main/15598/3570652/1582357.pdf
(c) 2022 Cision. All rights reserved., source